emteq labs

Emteq operates at the intersection of smart glasses, affective computing, digital health and human-computer interaction. Its differentiation is the use of facial-muscle activity and biometric responses to infer emotional or behavioral states, rather than relying primarily on cameras, voice or conventional motion sensors. The OCOsense platform is positioned as an open, low-latency sensing and analytics layer for healthcare, research and virtual or augmented environments. The closest visible market comparison is Ray-Ban Meta, which has helped establish smart glasses as a consumer interface, but Emteq’s stated emphasis is narrower and more clinically or analytically oriented: measuring facial expression, emotion and related behaviors. Its scientific positioning spans psychophysiology, machine learning, computer vision and facial musculature, while university collaborations and public innovation support provide evidence of research validation. Emteq therefore appears to occupy a specialized deep-technology niche rather than compete as a broad consumer-electronics brand.

Emteq’s trajectory shows a transition from research-led development toward a more defined wearable product and emotion-analytics platform. Founded in 2015, the company built its financing base through a 2019 seed round of $1.35 million led by NCL Technology Ventures, followed by grants, convertible notes and a $2.97 million angel round announced on Nov 1, 2024. Two equity-crowdfunding rounds in 2025 added a combined $131,613 and brought total recorded funding to $12.56 million. Product development has centered on OCOsense, an eyewear device using wireless, contact-free sensors to monitor facial-muscle activation and emotional responses. The 2024 wave of coverage in Wired, IEEE Spectrum, Tech Times and Healthcare Finance News marked an inflection point in public product visibility, while the 2025 “Monitoring mouth activities” patent indicates continued technical expansion. Leadership continuity is notable: Hristijan Gjoreski has served as CTO since 2018, Charles Nduka has held a scientific leadership role since 2015, and Steen Strand became CEO in 2024. Hiring growth, revenue, and customer scale are not publicly quantified.